J
Javier A. Menendez
Researcher at NorthShore University HealthSystem
Publications - 336
Citations - 29348
Javier A. Menendez is an academic researcher from NorthShore University HealthSystem. The author has contributed to research in topics: Cancer & Fatty acid synthase. The author has an hindex of 73, co-authored 317 publications receiving 25654 citations. Previous affiliations of Javier A. Menendez include Northwestern University & Boston Biomedical Research Institute.
Papers
More filters
Journal ArticleDOI
Metformin: a pharmacological approach integrating hyperinsulinemia breast cáncer at the molecular, cellular clinical levels*
TL;DR: The multifaceted and redundant mechanisms through which metformin-reprogrammed energy metabolism at both the organismal and the cellular level may constitute a novel and valuable strategy to prevent and treat breast cancer disease are reviewed.
gasification with CO 2
TL;DR: In this paper, a microwave-induced CO 2 gasification of carbon materials is proposed for energy storage, which is able to achieve energy efficiencies of 45% at laboratory scale with every indication that these results can be improved upon to make this approach highly competitive against other energy storage technologies.
Journal ArticleDOI
Silibinin Overcomes EMT-Driven Lung Cancer Resistance to New-Generation ALK Inhibitors
Sara Verdura,Jose A. Encinar,Eduard Bartoll Teixidor,Antonio Segura-Carretero,Vicente Micol,Elisabet Cuyàs,Joaquim Bosch-Barrera,Javier A. Menendez +7 more
TL;DR: In this paper , the authors investigated whether the mere process of EMT is sufficient to foster the resistance of lung cancer cells to various generations of ALK tyrosine kinase inhibitors (TKIs).
Posted ContentDOI
A multiscale model of epigenetic heterogeneity reveals the kinetic routes of pathological cell fate reprogramming
TL;DR: A stochastic model of combined epigenetic regulation (ER)-gene regulatory network (GRN) is introduced to study the plastic phenotypic behaviours driven by ER heterogeneity and the results suggest that epigenetic heterogeneity regulates the mechanisms and kinetics of phenotypesic robustness of cell fate reprogramming.
Journal ArticleDOI
The practice-changing QUARTZ trial: is there any role for whole brain radiotherapy in patients with non-small cell lung cancer and brain metastases?
TL;DR: This molecular approach might help, in addition to clinical variables, to define the patients that will obtain less benefit from WBRT and/or to design new targeted therapies to reverse radioresistance and improve the results of radiotherapy treatment when indicated.